CLINICAL RESEARCH: HEART FAILURE
Beta-Blockers for Primary Prevention of Heart Failure in Patients With HypertensionInsights From a Meta-Analysis
Sripal Bangalore, MD, MHA,
David Wild, MD,
Sanobar Parkar, MD, MPH,
Marrick Kukin, MD, FACC and
Franz H. Messerli, MD, FACC*
Department of Medicine, Division of Cardiology, St Luke's Roosevelt Hospital and Columbia University College of Physicians and Surgeons, New York, New York
Manuscript received October 26, 2007;
revised manuscript received May 7, 2008,
accepted May 13, 2008.
* Reprint requests and correspondence: Dr. Franz H. Messerli, Division of Cardiology, St. Luke's-Roosevelt Hospital, Columbia University College of Physicians and Surgeons, 1000 10th Avenue, Suite 3B-30, New York, New York 10019 (Email: messerli.f{at}gmail.com).
Objectives: This study sought to evaluate the efficacy of beta-blockers (BBs) for primary prevention of heart failure (HF) in patients with hypertension.
Background: The American College of Cardiology/American Heart Association staging for HF classifies patients with hypertension as stage A HF, for which BBs are a treatment option. However, the evidence to support this is unknown.
Methods: We conducted a MEDLINE/EMBASE/CENTRAL search of randomized controlled trials that evaluated BB as first-line therapy for hypertension with follow-up for at least 1 year and with data on new-onset HF. The primary outcome was new-onset HF. Secondary outcomes were all-cause mortality, cardiovascular mortality, myocardial infarction, and stroke.
Results: Among the 12 randomized controlled trials, which evaluated 112,177 patients with hypertension, BBs reduced blood pressure by 12.6/6.1 mm Hg when compared with placebo, resulting in a 23% (trend) reduction in HF risk (p = 0.055). When compared with other agents, the antihypertensive efficacy of BBs was comparable, which resulted in similar but no incremental benefit for HF risk reduction in the overall cohort (risk ratio: 1.00; 95% confidence interval: 0.92 to 1.08), in the elderly ( 60 years) or in the young (<60 years). Analyses of secondary outcomes showed that BBs confirmed similar but no incremental benefit for the outcomes of all-cause mortality, cardiovascular mortality, and myocardial infarction but increased stroke risk by 19% in the elderly.
Conclusions: In hypertensive patients, primary prevention of HF is strongly dependent on blood pressure reduction. When compared with other antihypertensive agents, there was similar but no incremental benefit of BBs for the prevention of HF. However, given the increased risk of stroke in the elderly, BBs should not be considered as first-line agents for prevention of HF.
Key Words: beta-blockers • heart failure • hypertension • meta-analysis
|
Abbreviations and Acronyms
| | ACC = American College of Cardiology | | ACEI = angiotensin-converting enzyme inhibitor | | AHA = American Heart Association | | ARB = angiotensin receptor blocker | | BB = beta-blocker | | CAD = coronary artery disease | | CCB = calcium-channel blocker | | CI = confidence interval | | HF = heart failure | | RCT = randomized controlled trial |
|
Related Articles
-
Hypertension, Heart Failure, and Beta-Adrenergic Blocking Drugs
- Michael B. Fowler
J. Am. Coll. Cardiol. 2008 52: 1073-1075.
[Full Text]
[PDF]
-
Inside This Issue of JACC
J. Am. Coll. Cardiol. 2008 52: A34.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
R. Kalaitzidis and G. Bakris
Should nephrologists use beta-blockers? A perspective
Nephrol. Dial. Transplant.,
December 10, 2008;
(2008)
gfn695v1.
[Full Text]
[PDF]
|
|
|
|
|
|
|
{beta}-Blockers to Prevent Heart Failure in Hypertensive Patients?
Journal Watch (General),
November 26, 2008;
2008(1126):
5 - 5.
[Full Text]
|
|
|
|
|
|
|
M. B. Fowler
Hypertension, Heart Failure, and Beta-Adrenergic Blocking Drugs
J. Am. Coll. Cardiol.,
September 23, 2008;
52(13):
1073 - 1075.
[Full Text]
[PDF]
|
|
|
|
